Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Placenta. 2017 Nov 10;61:33–38. doi: 10.1016/j.placenta.2017.11.004

Figure 1. C19MC miRNAs confer resistance to ZIKV.

Figure 1

(A) U2OS osteosarcoma cells were transfected with a non-targeting control miRNA mimic, a pool of 4 miRNAs from the C19MC (miR-512-3p, miR-525-5p, miR-516b-5p, and miR-517a) to a final concentration of 40 nM, or a corresponding concentration of non-C19MC miRNA mix (miR-141, miR-29b, miR-320). PHT conditioned medium (CM), prepared as described in Methods, was used as a positive control. At 48 h after transfection, cells were infected with VSV for 5 h, and viral RNA levels were determined by RT-qPCR. (B) the same experiment was performed using ZIKV, infected for 24 h. (C) Cellular miRNA levels for miR-512-3p, miR-517a, and miR-516b-5p were measured by RT-qPCR from ESC differentiated into an early trophoblast lineage at day 0, 2, 4, 6, and 8. Differences were determined using ANOVA, with post hoc Bonferroni correction. Experiments were performed three independent times. Data are shown as mean ±SD. (*p<0.05).